In HFCD-fed mice, liraglutide and teduglutide both significantly decreased hepatic weight, triglyceride and total cholesterol content, and macrovesicular steatosis scores, as well as plasma ALT, AST, and AP levels, compared with vehicle (Table 4; Fig. 9). This evidence concerns the gene GPT and steatosis.